U.S. Paper and Forestry Products Stock News

If you are wondering whether Uranium Energy is priced attractively right now, the first step is to separate the eye catching share price moves from the company’s underlying value. The stock most recently closed at US$15.55, with returns of 6.9% over 7 days, 20.4% over 30 days, 18.6% year to date, 125.4% over 1 year and a very large gain over 5 years. Recent attention on uranium related names, including Uranium Energy, has focused on supply security, nuclear power policy discussions and how...

If you are wondering whether Palantir Technologies is priced for perfection or still offers value, starting with a clear look at the current share price and fundamentals can help frame the next move. The stock has seen a 0.4% decline over the last 7 days and a 2.5% decline over the last 30 days, yet it is still up 6.6% year to date and 171.5% over the last year, with a very large 3 year return and a more than 5x 5 year return. Recent discussion around Palantir has focused on its role in...

Conference guidance puts Q4 and 2025 in sharper focus Danaher (DHR) updated its fourth quarter 2025 outlook ahead of the J.P. Morgan Healthcare Conference, indicating that Q4 core revenue and non-GAAP earnings are tracking toward the upper end of its previous guidance range. Management also highlighted strong bioprocessing performance and better than expected Life Sciences and Diagnostics revenue for the quarter. This update sets the stage for CEO Rainer M. Blair’s detailed comments at the...

Redwire (RDW) is reshaping its business after fully integrating the Edge Autonomy acquisition, unifying uncrewed aerial systems and defense technology under one brand while restructuring around two core segments: Space and Defense Tech. See our latest analysis for Redwire. Redwire's share price has recently cooled, with a 1-day share price return showing a 4.88% decline after earlier gains. The 30-day share price return of 39.09% suggests momentum has recently been building, even as the...

If you are wondering whether SM Energy is a bargain or a value trap at its recent price around US$18.17, you are asking the right question. The stock has had a tough run, with a 7.1% decline over the last 30 days, a 5.0% drop year to date, and a 56.9% fall over the past year, even though the 5 year return sits at 124.6%. Recent moves in SM Energy have come against a backdrop of ongoing attention on US oil and gas producers, sector wide capital discipline, and investor focus on balance sheet...

Earlier this week, NVIDIA and Eli Lilly and Company unveiled a first-of-its-kind AI co-innovation lab in South San Francisco, committing up to US$1.00 billion over five years to fuse Lilly’s drug discovery expertise with NVIDIA’s BioNeMo platform, accelerated computing and AI infrastructure. The collaboration’s continuous learning system, linking automated wet labs with AI-powered dry labs and digital twins of manufacturing, could materially reshape how Lilly discovers, develops and produces...

If you are wondering whether Oracle's current share price really lines up with its business fundamentals, you are not alone. That is exactly what this article will unpack for you. Oracle's stock last closed at US$202.29, with returns of 4.4% over 7 days, 6.5% over 30 days, 3.4% year to date, 30.7% over 1 year, 136.7% over 3 years and 253.4% over 5 years. This naturally raises questions about what a fair price might look like now. Recent news around Oracle has focused on its broader position...

Why HCI Group (HCI) Is Back in Focus Ahead of Earnings HCI Group (HCI) is drawing attention after its share price slipped 1.87% in the latest session, as investors look ahead to an upcoming earnings report that is expected to show very large EPS growth versus last year. See our latest analysis for HCI Group. At a share price of US$176.06, HCI Group has had a mixed stretch recently, with a 1 month share price return of a 6.09% decline and a 3 month share price return of a 12.76% decline...

PC Connection (CNXN) has been in focus after reporting quarterly revenue of US$709.1 million, a 2.2% year-on-year decline that missed analyst revenue and EPS estimates, with the stock down about 4% since the release. See our latest analysis for PC Connection. At a share price of US$58.78, the recent 4% pullback after the results comes on top of a 1-year total shareholder return decline of 15.38%. However, the 3-year and 5-year total shareholder returns of 20.17% and 20.41% present a more...

BlackRock (BLK) has drawn fresh attention after announcing a global workforce reduction of about 1% shortly after reporting stronger than expected quarterly earnings and reporting increased institutional flows into its exchange traded funds. See our latest analysis for BlackRock. BlackRock shares trade at US$1,089.54, with a 90 day share price return of a 9.4% decline but a 1 year total shareholder return of 15.44%. This suggests longer term holders have seen stronger gains even as recent...

Prestige Consumer Healthcare (PBH) just moved to expand its TheraTears eye care line, announcing nationwide February 2026 launches for Eyelid Cleansing Wipes and Dry & Tired preservative free lubricant eye drops targeting screen related eye fatigue. See our latest analysis for Prestige Consumer Healthcare. The fresh TheraTears launches sit alongside a recent run of conference appearances and an upcoming fiscal 2026 third quarter earnings release. This is during a period where the share price...

President Donald Trump’s proposal for a US$200b mortgage bond purchase plan, paired with assurances that Opendoor Technologies (OPEN) is not targeted by a potential institutional buying ban, sparked fresh interest in the iBuyer’s rate sensitive stock. See our latest analysis for Opendoor Technologies. Those policy headlines have come after an already eventful stretch for Opendoor, with recent mortgage bond proposals, leadership changes and the Homebuyer.com acquisition all feeding into a rate...

IDEXX Laboratories (IDXX) has put a firm CEO succession plan in place, with Michael Erickson set to become President and Chief Executive Officer on May 12, 2026, as Jonathan Mazelsky moves to Executive Chair. See our latest analysis for IDEXX Laboratories. The CEO succession news comes after a strong run for long term holders, with the 1 year total shareholder return at 70.57% and the 5 year total shareholder return at 47.25%. The recent 90 day share price return of 11.72% suggests momentum...

Earlier in January 2026, Duolingo announced that long-time board member and Audit Chair Gillian Munson will become Chief Financial Officer on February 23, 2026, succeeding outgoing CFO Matt Skaruppa, who will shift to an advisory role to support a smooth transition. The company paired this leadership change with preliminary fourth-quarter 2025 figures showing strong year-over-year growth in daily active users and bookings, even as management emphasized ongoing product investment over...

If you are trying to figure out whether GE Vernova's current share price really makes sense, you are in the right place. The stock is up 71.0% over the last year, even though it has seen a 5.0% decline over the past week, a 2.9% decline over the past month and a 4.0% decline year to date from its last close of US$652.09. Recent news coverage has focused on GE Vernova's position in the capital goods space and how investors are responding to its role in the wider energy transition. This...

If you are wondering whether RenaissanceRe Holdings is still good value at around US$270.10 per share, this breakdown is designed to help you make sense of the current price. The stock’s moves have been relatively muted recently, with a 0.7% decline over the last week, a 0.8% decline over the past month and year to date, and an 8.2% return over one year and 76.5% over five years. Recent attention on RenaissanceRe has centered on how the company is positioned within the insurance and...

Ichor Holdings, Ltd. ( NASDAQ:ICHR ) shares have had a really impressive month, gaining 47% after a shaky period...

Key Insights Given the large stake in the stock by institutions, NewtekOne's stock price might be vulnerable to their...

As the U.S. stock market grapples with fluctuating bank earnings and inflation data, major indices like the Dow Jones, S&P 500, and Nasdaq have experienced recent declines. Amidst this volatility, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential market inefficiencies and secure assets at a discount.

As the U.S. stock market navigates through a period marked by fluctuating bank earnings, inflation concerns, and record highs in precious metals, investors are keenly observing sectors that could offer potential growth amid these uncertainties. In such an environment, companies with high insider ownership often attract attention as they may indicate confidence from those who know the business best.

As major stock indexes in the United States face volatility due to recent bank earnings, inflation data, and fluctuating retail sales figures, investors are seeking alternative opportunities beyond traditional blue-chip stocks. Penny stocks, a term that might seem outdated but remains significant for many investors, often represent smaller or newer companies with potential for growth at lower price points. In this article, we explore three penny stocks that stand out for their financial...

As the U.S. market navigates through a period of fluctuating indices and economic indicators, small-cap stocks present unique opportunities amid broader market volatility. In this landscape, identifying promising companies requires a keen eye for innovation and resilience, particularly those that can thrive despite challenges such as inflationary pressures and shifting consumer trends.

In January 2026, PTC Therapeutics issued full-year 2026 guidance, projecting total product revenue of US$700 million to US$800 million, excluding Evrysdi royalty and collaboration revenue, while also reporting stronger-than-expected preliminary 2025 product and royalty results driven by Sephience. The company coupled its outlook with updates on regulatory and pipeline progress, including FDA alignment on a Phase 3 Huntington’s trial for votoplam and continued engagement on vatiquinone and...

Natural Resource Partners (NRP) recently set a new 52 week high at US$111.15 after releasing solid third quarter 2025 earnings. This has put fresh attention on how the partnership’s mineral and royalty profile is being valued. See our latest analysis for Natural Resource Partners. At the latest share price of US$114.20, NRP’s recent 1 month share price return of 9.42% and year to date share price return of 9.80% sit alongside a very large 5 year total shareholder return. This suggests...